Search Results

Ascendis Pharma A/S announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.

Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, Pliant is paring back its workforce.

electroCore, Inc. announced it has entered into an agreement with Teijin Limited, a global conglomerate based in Japan offering advanced solutions in the fields including healthcare, material and information technology, to license certain exclusive rights to its non-invasive vagus nerve stimulation technology for commercialization in Japan for a range of primary headache disorders.

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited, a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions.